Dianthus Therapeutics (DNTH) Non-Current Assets (2017 - 2025)

Dianthus Therapeutics' Non-Current Assets history runs 9 years deep, the most recent figure standing at $121.5 million for Q4 2025.

• In Q4 2025, Non-Current Assets rose 30.48% year-over-year to $121.5 million; the TTM figure through Dec 2025 stood at $425.2 million (up 158.19% YoY), while the FY2025 annual figure was $121.5 million, up 30.48% from the prior year.
• Non-Current Assets was $121.5 million for Q4 2025 at Dianthus Therapeutics, down from $163.6 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $163.6 million in Q3 2025 to a low of $1.0 million in Q3 2023.
• Historically, Non-Current Assets has averaged $40.7 million across 5 years, with a median of $21.1 million in 2021.
• The sharpest annual moves came in 2023 and 2024: Non-Current Assets sank 96.85% in 2023, then soared 6516.35% in 2024.
• A 5-year view of Non-Current Assets shows it stood at $9.2 million in 2021, then slumped by 88.35% to $1.1 million in 2022, then surged by 81.43% to $2.0 million in 2023, then surged by 4664.79% to $93.1 million in 2024, then surged by 30.48% to $121.5 million in 2025.
• The last three Non-Current Assets figures came in at $121.5 million (Q4 2025), $163.6 million (Q3 2025), and $62.5 million (Q2 2025), per Business Quant data.